U-22956

Aminoglycoside
The UpJohn Company
1964

  • Highest development stage: Preclinical

  • Development dropped

  • Gram-positive activity

  • Gram-negative activity

  • Mechanism of Action/Target pathogen: Active in vivo against Gram-positive and Gram-negative bacteria but poor protection in a mouse model

  • Reason dropped: Limited in vitro activity

  • Additional information: Mason, D.J "U-22956, A new antibiotic" Program and Abstracts of the interscience science Conference on Antimicrobial Agents and Chemotherapy. 1964.

  • Citation (1): https://pubmed.ncbi.nlm.nih.gov/14287912/